[PDF]3 01-05-2016 Class II IgG - Rackcdn.comhttps://75c17d9f6eecafb09b78-695e1a25d6559f5c6a6714b54be309d0.ssl.cf3.rackcd...
7 downloads
151 Views
198KB Size
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 01/2016 DESPATCHED ON 26TH JANUARY 2016 HLA specificity for assessment DR17 DR18 Consensus Absent Absent 1.3% 1.3% % reported Lab no. spec tech MFI spec tech MFI 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 101 112 114 116 117 119 120 133 136 139 142 143 145 147 149 157 159 160 162 163 164 165 169 181 185 186 190 193 194 195 197 204 206 209 218 227 232 DR17 L > 5000 DR18 L > 5000 235 238 245 262 267 268 273 277 284 292 293 294 297 303 309 311 315 323 Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other No. Reporting Spec Total Participants
1 80
< 2000 0 2000-5000 0 > 5000 1
1 80
< 2000 0 2000-5000 0 > 5000 1
DR4 Present 91.3% spec DR4 L DR4 L DR4 L
tech
MFI < 2000 < 2000 2000-5000
DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4
L L L L L L L L L L L L L L L L L L L L L L L L L EL L L L L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 < 2000 2000-5000 2000-5000,> 5000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000,2000-5000
DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4
L L L L L L L FEL L L L L L L
< 2000 2000-5000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 2000-5000 < 2000
DR4
L
2000-5000
DR4 DR4 DR4 DR4 DR4
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4
L L L L L L L L L L L L L L L
< 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000
DR4
L
< 2000
DR7 Absent 1.3% spec
DR7
tech
L
MFI
DR8 Absent 1.3% spec
< 2000
DR8
73 80
< 2000 52 2000-5000 19 > 5000 1
1 80
< 2000 1 2000-5000 0 > 5000 0
tech
1 80
L
< 2000 0 2000-5000 0 > 5000 1
DQ7 Present 100.0% MFI spec DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 > 5000 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7
80 80
tech L L L L L L CL L L L L L L L L L L L L L L L L L L L L L L EL L L L L L L L L L L L L L L L L FEL L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
< 2000 0 2000-5000 0 > 5000 79
MFI > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
DQ8 Present 98.8% spec DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L EL L L L L L L L L L L L L L L L L FEL L L L L L L L L L L L L L L L
DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8
L L L L L L L L L L L L L L L L L
79 80
tech
< 2000 0 2000-5000 0 > 5000 78
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000
DQ9 Present 98.8% spec DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L EL L L L L L L L L L L L L L L L L FEL L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9
L L L L L L L L L L L L L L L L L
MFI > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
79 80
tech
MFI > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
< 2000 0 2000-5000 0 > 5000 78
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-120 Issue 1 P 1 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 01/2016 DESPATCHED ON 26TH JANUARY 2016
Lab no. 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 101 112 114 116 117 119 120 133 136 139 142 143 145 147 149 157 159 160 162 163 164 165 169 181 185 186 190 193 194 195 197 204 206 209 218
Techniques used IgG
Sample Treatment IgG
High Background
L L L L L L C, L L L L L L L L L L L L L L L L L L L L L C, L C, L EL L L L
None
No No No No No No No No Yes
EDTA Heat Inactivation, EDTA EDTA EDTA wash buffer EDTA None EDTA, Adsorption beads EDTA EDTA None EDTA None EDTA EDTA wash buffer None EDTA EDTA, Adsorption beads Heat Inactivation Adsorption beads EDTA None None None None EDTA None None EDTA EDTA None
L L L L L L
None EDTA None None
L L L L L L F, E, L L L L L L L L L L L L C, L L
EDTA None Adsorption beads EDTA EDTA None Dilution Dilution None EDTA None EDTA None DTT None None EDTA EDTA EDTA Heat Inactivation
No No No No No No No No No Yes No No No No No No No No Yes No
Yes No No No No
No No No No No
Allele Specific Antibodies
Luminex kit (lot)
Cut-off value
IgG
IgG
IgG
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
500 500 500 1500 1000 1000 500 1000 1000 1000 1000 500 660 1000 1840 2000
LS2A01 LS2A01 LS2A01 LS2A01 LSAII LS2A01 LSAII LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LSAII
800 750 1000 1000 1072 1000
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
DPB1*14:01
DRB1*04:04
DQA1*03:01, 03:02, 05:03, 05:05, 06:01
DRB1*04:01, 04:02, 04:03, 04:05 DQB1*03:01, 03:02, 03:03 DQA1*03:01, 03:02, 05:03, 05:05, 06:01
MICA = positive
No
Control bead MFI Positive
Control bead MFI Negative
9000 76 12279 12892 12790.03 14931 10515 10819 12973 17457 10330 10836 12450 13524 11382 13913 12138 10160 13180
273 6261 329 139 15.23 115 117 63 50 955 132 180.87 90 242 116 69 91 62 132
11073 14177 12135 14839 15927 10615 20316 16204 8227 11726 7147 11251 16536
169 118 206 128 107 130 230 44 71 148 44 87 74
1000 1000 1000 1000 1000 1500
11485 11990 9329 12306 13273 9784
90 103 106 104 245 75
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
1000 1500 1000 1000 1500 1500 110
11400 9928 10700 13100 15037 17310 15049
61.5 182 72 75 234 144 136
LS2A01 LSAII LSM12 LS2A01 LS2A01 LS2A01 LS2A01
500 1000 1000 1000
12230 18820 13547 10500 10624
97 110 333 111 76
1400
15300
105
LS2A01 LS2A01 LS2A01 LSAII
1000 1000 500
12133 10925 3000 14937
93 80 500 95
9191 14540 19064 13571 17858 19725 16670 12016 8288 10006 13379 10429 16352 9795 8838 18000 12552 10475 13919
37 396
1000 1500
1000 1000 500 1000 500
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LSM12 LSM12
2.5 3
176 17010
7546 587
LS2PRA
1000
14749.84
254.85
LS2PRA LSAII
1000 1500
17069 19247
2442 108
LSAII
1541
17274
108
LSM12 LSM12
350 3
12939 11820
120 158
LSM12
12356
306
LSM12
1.5
12737
62
LSM12
6
12203
180
LSM12 LSM12
1.5/1.2 5
7991 9326
49 29
LSM12
3
19600
468
LM2 LSA I&II
1000
22607 19256
38 95
LSM12
1000
8096
348
LMX LM2
1000
20574
78/99/123
LSM12 LSM12 LS2PRA
3 2.5 500
10258 12155 10429
87 78 18
Luminex kit (lot)
Cut-off value
Control bead MFI Negative
Cut-off value
IgG
Control bead MFI Positive
Luminex kit (lot)
IgG
IgG
IgG
LSAII
default
19623
107
LMX
LSAII
12999
113
LMX
Control bead MFI Positive
Control bead MFI Negative
18768
16683
DQA1*03:02, 05:03, 05:05, 06:01 No No No No
No No No No
DRB1*04:01, 04:02, 04:03, 04:05 DQB1*03:01, 03:02, 03:03 227 L Dilution, EDTA No 232 L None No DQA1*03:01, 03:02, 05:03, 05:05, 06:01 235 L DTT, Adsorption beads Yes 238 L None No 245 L EDTA No 262 L None No 267 L None No 268 C, L None No 273 L None No 277 L EDTA No 284 L EDTA No 292 L No DQA1*03:02, 05:03, 05:05, 06:01 293 L None 294 L None 297 L EDTA No 303 L EDTA No 309 L None No 311 L EDTA No 315 L EDTA No 323 L EDTA No Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other
LS2A01 LS2PRA LSAII LS2A01 LSAII LSAII LSAII LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LSAII LS2A01 LS2A01 LSAII LS2A01 LS2A01 LS2A01
1000 500 1000/500 AD BCR >5 BCM >700 1500 1717 500 1000 500 500 1500 1000 900 1500 2000 1000
154 116 115 113 195 71 64 81 18
LMX
156 90 109 139 779 49
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-120 Issue 1 P 2 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 02/2016 DESPATCHED ON 26TH JANUARY 2016 HLA specificity for assessment DR1 DR103 Consensus Not Assessed Not Assessed 11.3% 18.8% % reported Lab no. spec tech MFI spec DR103 9 11 DR103 12 14 15 19 DR103 20 23 DR103 24 25 26 DR103 28 DR103 34 35 38 39 41 DR103 42 45 48 DR103 51 DR103 54 58 62 DR1 L < 2000 100 101 DR1 L < 2000 112 DR103 114 116 DR103 117 119 DR103 120 DR1 L < 2000 133 136 139 142 143 145 147 DR1 L < 2000 149 157 159 160 162 163 164 165 169 DR103 181 185 186 190 193 194 195 197 204 206 DR103 209 DR1 L < 2000 218 227 232 235 DR1 L < 2000 238 DR103 245 262 DR1 L < 2000 267 268 273 277 284 292 293 DR1 L < 2000 294 297 303 DR1 L 2000-5000 309 311 315 323 Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other No. Reporting Spec Total Participants
9 80
< 2000 8 2000-5000 1 > 5000 0
15 80
L
tech
MFI < 2000
L
< 2000
L
< 2000
L
< 2000
L L
< 2000 < 2000
DR16 Not Assessed 13.8% spec
< 2000
L L
< 2000 < 2000
L
< 2000
L
< 2000
L
< 2000
MFI
DR17
L
L
< 2000
DR16
L
< 2000
L
L
L
L
L
< 2000
< 2000
F
DR18
F
< 2000
< 2000 DR16
< 2000 15 2000-5000 0 > 5000 0
L
DR18
DR17
L
< 2000 DR18
tech
L
< 2000
DR16
L
< 2000
DR16 DR16
L L
2000-5000 < 2000
< 2000
DR16
L
< 2000
DR16
L
2000-5000
11 80
< 2000 9 2000-5000 2 > 5000 0
MFI
< 2000
< 2000
< 2000
DR16
DR16
L
L
MFI
DR18
DR16
L
tech
DR18 Not Assessed 6.3% spec
DR18
DR16
L
tech
DR17 Absent 2.5% spec
2 80
< 2000 1 2000-5000 0 > 5000 0
5 80
< 2000 4 2000-5000 0 > 5000 0
< 2000
< 2000
DR4 Present 100.0% spec DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4 DR4
80 80
tech L L L L L L L L L L L L L L L L L L L L L L L L L L L L L EL L L L L L L L L L L L L L L L L FEL L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
< 2000 1 2000-5000 16 > 5000 62
MFI > 5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000,> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 < 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
DR12 Not Assessed 6.3% spec
tech
MFI
DR7 Absent 5.0% spec
DR7
DR12
L
< 2000 DR7
DR7
DR12
L
< 2000
DR12
L
< 2000
DR12
L
< 2000
DR12
L
< 2000 DR7
5 80
< 2000 5 2000-5000 0 > 5000 0
4 80
tech
L
L
L
L
< 2000 3 2000-5000 1 > 5000 0
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
MFI
< 2000
DR8 Absent 1.3% spec
DR8
tech
L
MFI
DR9 Not Assessed 50.0% spec DR9 L
tech
MFI < 2000
< 2000 DR9
L
2000-5000
DR9
L
< 2000
DR9
L
< 2000
DR9
L
< 2000
DR9 DR9
L L
< 2000 < 2000
DR9 DR9
L L
2000-5000 < 2000
DR9 DR9
L L
< 2000 < 2000
DR9 DR9 DR9 DR9
L L L L
< 2000 < 2000 < 2000 2000-5000
DR9
L
< 2000
DR9 DR9 DR9 DR9 DR9
L L EL L L
2000-5000 < 2000 2000-5000 < 2000 < 2000
DR9
L
< 2000
DR9 DR9 DR9
L L FL
< 2000 < 2000 2000-5000
DR9
L
< 2000
DR9 DR9 DR9
L L L
< 2000 < 2000 < 2000
DR9
L
< 2000
DR9
L
< 2000
DR9
L
< 2000
DR9
L
< 2000
DR9 DR9 DR9 DR9
L L L L
< 2000 < 2000 < 2000 < 2000
DR9 DR9
L L
< 2000 < 2000
DR9
L
2000-5000
< 2000
2000-5000
< 2000
1 80
< 2000 1 2000-5000 0 > 5000 0
40 80
< 2000 33 2000-5000 7 > 5000 0
NEQ-120 Issue 1 P 3 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 02/2016 DESPATCHED ON 26TH JANUARY 2016 HLA specificity for assessment DR51 DR53 Consensus Absent Absent 5.0% 3.8% % reported Lab no. spec tech MFI spec tech MFI 9 11 < 2000 DR53 L < 2000 12 DR51 L 14 15 19 < 2000 20 DR51 L 23 24 25 26 28 DR51 L 34 35 38 39 41 42 45 48 51 54 58 62 100 101 112 < 2000 DR53 L < 2000 114 DR51 L 116 117 119 120 133 136 139 142 143 145 147 149 157 159 160 162 163 164 165 169 181 185 186 190 193 194 195 197 204 206 209 218 227 232 235 238 245 262 267 268 273 277 284 DR53 L < 2000 292 293 294 297 303 309 311 315 323 Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 4 80
< 2000 3 2000-5000 0 > 5000 0
3 80
< 2000 3 2000-5000 0 > 5000 0
DQ5 Not Assessed 8.8% spec
tech
MFI
DQ6 Not Assessed 6.3% spec
tech
MFI
DQ2 Not Assessed 33.8% spec DQ2 L
tech
MFI < 2000
DQ5
L
< 2000 DQ6
L
< 2000 DQ2
L
2000-5000
DQ5
L
< 2000 DQ6
L
< 2000 DQ2 DQ2 DQ2
L L L
< 2000 < 2000 < 2000
DQ5
L
DQ2
L
DQ2
L
DQ5
L
< 2000
DQ5
L
< 2000 DQ6
L
DQ6
DQ5
L
DQ5
L
7 80
< 2000 6 2000-5000 0 > 5000 0
MFI > 5000
L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 < 2000
tech
MFI > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 2000-5000
MFI > 5000
L L L L L L L L L L L L L L L L
> 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000
> 5000 > 5000
DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9 DQ9
< 2000
< 2000
< 2000 4 2000-5000 0 > 5000 0
tech
MFI < 2000
L
2000-5000
DQ7
L
2000-5000
DQ8
L
> 5000
DQ9
L
> 5000
DQ2 DQ2
L L
< 2000 < 2000
DQ7 DQ7 DQ7
L L L
2000-5000 2000-5000 > 5000
DQ8 DQ8 DQ8
L L L
> 5000 2000-5000 > 5000
DQ9 DQ9 DQ9
L L L
> 5000 2000-5000 > 5000
DQ4 DQ4 DQ4
L L L
> 5000 > 5000 > 5000
DQ7
L
2000-5000
DQ8
L
2000-5000
DQ9
L
2000-5000
DQ4
L
2000-5000
DQ8 DQ8 DQ8 DQ8 DQ8
L L EL L L
> 5000 > 5000 2000-5000 > 5000 > 5000
DQ9 DQ9 DQ9 DQ9
L L L L
> 5000 > 5000 > 5000 > 5000
DQ4 DQ4 DQ4 DQ4 DQ4
L L L L L
> 5000 > 5000 > 5000 2000-5000 > 5000
DQ8 DQ8 DQ8
L L L
> 5000 2000-5000 < 2000,2000-5000
DQ9 DQ9 DQ9
L L L
> 5000 2000-5000 < 2000,2000-5000
DQ4 DQ4 DQ4 DQ4 DQ4
L L L L L
2000-5000 > 5000 > 5000 > 5000 2000-5000
L L L L FL L
> 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000
2000-5000
L L L L L L L L L L L L L L L L
tech
DQ4 Not Assessed 70.0% spec DQ4 L
DQ2
2000-5000 < 2000 2000-5000
DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8
DQ9 Not Assessed 63.8% spec DQ9 L
DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4 DQ4
< 2000
DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7 DQ7
DQ8 Not Assessed 68.8% spec DQ8 L
2000-5000 > 5000 > 5000
2000-5000 > 5000 > 5000 > 5000 > 5000
DQ2 DQ2 DQ2
L L L
< 2000 < 2000 2000-5000
DQ7 DQ7 DQ7
L L L
2000-5000 2000-5000 > 5000
DQ2
L
< 2000
DQ7
L
2000-5000
DQ7
L
< 2000,2000-5000
DQ7
L
< 2000
DQ7
L
< 2000
DQ8
L
2000-5000
DQ9
L
2000-5000
DQ7
L
> 5000
DQ8
L
> 5000
DQ9
L
> 5000
< 2000
F
5 80
tech
< 2000
L
DQ6
DQ7 Not Assessed 57.5% spec DQ7 L
L L L L L L L L L L L L L L L L L L
> 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 > 5000
DQ2 DQ2
FL L
2000-5000 < 2000
DQ7 DQ7
FL L
2000-5000 2000-5000
DQ8 DQ8
FL L
> 5000 > 5000
DQ9 DQ9
FL L
> 5000 > 5000
DQ4 DQ4 DQ4 DQ4 DQ4 DQ4
DQ2 DQ2 DQ2
L L L
2000-5000 < 2000 < 2000
DQ7 DQ7 DQ7 DQ7
L L L L
> 5000 2000-5000 < 2000 2000-5000
DQ9 DQ9 DQ9 DQ9
L L L L
> 5000 > 5000 2000-5000 > 5000
DQ4 DQ4 DQ4 DQ4
L L L L
> 5000 > 5000 2000-5000 > 5000
L L L
> 5000 < 2000 < 2000
DQ7 DQ7 DQ7
L L L
> 5000 < 2000 2000-5000
L L L L L L L L
> 5000 > 5000 2000-5000 > 5000
DQ2 DQ2 DQ2
DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8 DQ8
> 5000 2000-5000 > 5000
DQ9 DQ9 DQ9
L L L
> 5000 2000-5000 > 5000
DQ4 DQ4 DQ4
L L L
> 5000 2000-5000 > 5000
DQ2
L
2000-5000
DQ7
L
2000-5000
DQ8 DQ8 DQ8
L L L
> 5000 > 5000 > 5000
DQ9 DQ9
L L
> 5000 > 5000
DQ4 DQ4
L L
> 5000 2000-5000
DQ2
L
2000-5000
DQ7 DQ7
L L
2000-5000 2000-5000
DQ8 DQ8
L L
> 5000 2000-5000
DQ9
L
> 5000
DQ4
L
> 5000
DQ2
L
2000-5000
DQ7 DQ7
L L
2000-5000 2000-5000
DQ8 DQ8 DQ8
L L L
> 5000 > 5000 > 5000
DQ9 DQ9 DQ9
L L L
> 5000 > 5000 > 5000
DQ4 DQ4
L L
> 5000 > 5000
L L
2000-5000 2000-5000
DQ9 DQ9
L L
2000-5000 2000-5000
DQ4 DQ4
L L
> 5000 > 5000
DQ7
L
2000-5000
DQ8 DQ8
DQ2
L
< 2000
DQ7
L
2000-5000
DQ8
L
> 5000
DQ9
L
> 5000
DQ4 DQ4
L L
< 2000 2000-5000
DQ2
L
< 2000
DQ7
L
2000-5000
DQ8
L
> 5000
DQ9
L
> 5000
DQ4
L
> 5000
DQ8
L
2000-5000
DQ9
L
2000-5000
27 80
< 2000 17 2000-5000 8 > 5000 1
46 80
< 2000 8 2000-5000 29 > 5000 6
55 80
< 2000 0 2000-5000 16 > 5000 35
51 80
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
< 2000 0 2000-5000 13 > 5000 35
56 80
< 2000 2 2000-5000 15 > 5000 38
NEQ-120 Issue 1 P 4 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 02/2016 DESPATCHED ON 26TH JANUARY 2016 Sample Treatment IgG
High Background
Lab no. 9 L 11 L
Techniques used IgG
Dilution
Yes No
12
L
EDTA
No
14 15
L L
Heat Inactivation, EDTA EDTA
No No
19 20
L C, L
EDTA wash buffer EDTA
No No
23
L
None
No
24
L
EDTA, Adsorption beads
Yes
25 26
L L
EDTA None
28
L
None
No
34 35 38
L L L
EDTA None EDTA
No
39
L
EDTA wash buffer
No
41
L
None
No
42
L
EDTA
45
L
EDTA, Adsorption beads
No
48
L
Heat Inactivation
No
51
L
54
L
Adsorption beads
Yes
58
L
EDTA
No
62
L
None
No
100
L
None
No
101
L
None
No
112
L
None
No
114
C, L
EDTA
No
116
C, L
Adsorption beads
Yes
117
EL
None
No
119
L
EDTA, Adsorption beads
Yes
120 133
L L
EDTA None
No
136
L
Yes
No
No
139
L
None
Yes
142 143 145 147 149 157
L L L L
EDTA None None None
No No No
L
EDTA
No
159
L
None
160 162
L L
Adsorption beads EDTA
No No
163
L
EDTA
No
164
L
None
165 169 181
F, E, L L L
Dilution
185
L
EDTA
No
186 190
L L
None EDTA
No No
193
L
No
None
None
No
194
L
DTT
195 197 204
L L L
Adsorption beads None EDTA
No
206 209 218 227
L C, L L L
EDTA EDTA Heat Inactivation Dilution, EDTA
No No No No
No
232
L
None
No
235 238 245 262 267 268 273
L L L L L C, L L
DTT, Adsorption beads None EDTA None Sera Clean None None
Yes No No No Yes No No
277
L
EDTA
No
Allele Specific Antibodies
Luminex kit (lot)
Cut-off value
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
DQA1*03:01, 03:02, 03:03 DQA1*03:01, 03:02, 03:03 DPB1*11:01, 13:01 DRB5*01:01 DQB1*05:02, 06:02 DQA1*03 has been interpreted as causing positivity seen against DQB1*02:01, 03:01, 03:02, 03:03, 04:01 DQA1*02:01 has been interpreted as causing positivity seen against DQB1*03:01, 03:03, 04:01, 04:02 DPB1*01:01, 03:01, 05:01, 06:01, 11:01, 13:01 DPB1*11, 13 DRB1*09:02 DQB1*04:01; DQA1*03:01, 03:02, 03:03 DPB1*11, 13 DQB1*04:01; DQA1*03:01, 03:02 DRB5*01:01 DQB1*04:01, 04:02, 05:02, 06:02; DQA1*01:01, 01:02, 02:01, 03:01, 03:02, 03:03, 04:01 DPB1*01:01, 11:01, 13:01; DPA1*02:01, 02:02 DQA1*03:01, 03:02, 03:03 DP11, 13 DRB1*09:02 DQB1*04:01; DQA1*03:01, 03:02, 03:03 DPB1*11, 13 DQA1*03:01, 03:02, 03:03 DQB1*04:01; DQA1*02:01, 03:01, 03:02 DPB1*11:01, 13:01 DRB5*01:01 DQB1*04:01, 05:02; DQA2, 3 DPB1, 5 DQB1*04:01; DQA1*03:01, 03:02, 03:03 DQA1*03:01, 03:02, 03:03 DQA1*03 DPB1*13:01 DQB1*04:01; DQA1*03:01, 03:02, 03:03 Possible abs detected against DPA/DPB heterodimers: DPA1*02:01, DPB1*13:01; DPA1*02:02, DPB1*11:01; DPA1*02:02, DPB1*13:01 DQA1*03 DPA1*02:01, DPB1*13:01; DPA1*02:02, DPB1*11:01; DPA1*02:02, DPB1*13:01 DQA1*03 DPB1*01:01, 13:01 DQB1*04:01; DQA1*03 DPB1*11, 13 DQB1*04:01 DQA1*03:01, 03:02, 03:03 DQA1*03:01, 03:02, 03:03 DPB1*11, 13 DQA*02, 03 DPB*01, 11, 13 DQA1*03 DPB11, 13 DQA1*03 DPB1*11, 13 Not listed corresponding DQB Abs (DQ4, DQ7, DQ8, DQ9) associated with DQA Abs as we can determine these DQ Abs as negative DQA1*03:01, 03:02 DRB1*09:02 DQB1*04:01; DQA1*03:01, 03:02, 03:03 DPB1*13 DRB1*16:02 DQA1*03:01 DQB1*05:02; DQA1*02:01, 03:01, 03:02, 03:03 DP1, 6, 11, 13 DQA03:01 DP11, 13 DQA1*03:01, 03:02, 03:03 DP11, 13; DPA1*02:02 DRB1*09:02 DQB1*04:01; DQA1*03:01, 03:02, 03:03 (we do not consider as positive the corresponding DQB1*03:01, 02:01, 03:02 and 03:03) DQB1*04:01; DQA1*03:01, 03:02, 03:03 DRB1*01:02, 16:02 DQA1*03:01 DQA1*03:01, 03:02, 03:03 DP11, 13 DQA1*03 DPB1*13 DP11, 13
LS2A01 LS2A01
500 500
7780 185
465 6168
LSM12
2.5
258
6812
LS2A01
500
13978
416
LSM12
3
14941
1151
LS2A01 LS2A01
1500 1000
13019 12052
83 79
LS2A01 LS2A01
1000 500
12359 13213
43 220
LS2A01
1000
11086
825
LS2A01
1000
12145
47
LS2PRA
1000
16512
1118
LS2A01 LS2A01
1000 1000
11216 9265
303 170
LSAII
1500
19876
178
LSAII
807
18438
174
DQB1*04:01; DQA1*03:03 Dqalpha 0301, 0302, 0303 DQA1*03:01 DQA1*03:01, 03:02, 03:03 DP11, 13 DQA1*03:01, 03:02, 03:03 DP11, 13 DQB1*04:01; DQA1*03:01, 03:02, 03:03 MICA = negative DRB1*09:02 DQA1*03 DP13 DQB1*04:01; DQA1*03 DPB1*11, 13 DP1, 11, 13 DQA1*03:01, 03:02, 03:03 DP11, 13 HLA typing of patient required to interpret HLA-DR1, 16, 12: these could be false positive results in the Immucor LSA test and LM2 Class II is not reactive for these antigens DQA1*03 DQA*03:02 DQA1*03 DPB1*11, 13 DQA1*03:01, 03:02, 03:03 DPB1*11:01, 13:01 DQA1*03:01, 03:02, 03:03 DPB1*11, 13 DQA1*03:01 DRB1*09:02 DQA1*03 DP13 DQA1*03:01, 03:02, 03:03 DQA1*03:01, 03:02, 03:03 DRB1*01:02, 04:01, 04:02, 04:03 ,04:05, 16:02 DQB1*04:01; DQA1*03:01, 03:02, 03:03 DPB1*11, 13 DQA1*02:01, 03:01, 03:02, 03:03 DP11, 13; DPA1*02:01, 02:02 DQA1*03 (without DQB) DQB1*05:02; DQA1*03:01, 03:02, 03:03 (in our protocol HLA-DQ2, DQ7, DQ8 and DQ9 wouldn't be assigned as present) DQA1*03 DQA1*03:01, 03:02
DRB1*09:02 DQA1*02:01, 03:01, 03:02, 03:03 DPB1*13:01/DPA1*02:01; DPB1*13:01, DPA1*02:02; DPB1*11:01/DPA1*02:02 DQA1*03:01, 03:02, 03:03 DPB1*13:01/DPA1*02:01; DPB1*13:01, DPA1*02:02; DPB1*11:01/DPA1*02:02 284 DQA1*03 DPB1*11:01, 13:01 292 L EDTA, Adsorption beads Yes DRB1*09:02 DQA1*03:01, 03:02, 03:03 293 L None DP11, 13 294 L None DQA*03 297 L EDTA No DQA1*03:01, 03:02, 03:03 DPB1*11:01, 13:01 303 L EDTA No DQB1*04:01; DQA1*03 DP11, 13 309 L None No DQA1*03:01, 03:02 (not listed DQB'S because they are negative) 311 L EDTA, Adsorption beads Yes DQB1*04:01; DQA1*03 DP11, 13 315 L EDTA No DQA*03:01, 03:02, 03:03 323 L EDTA No DP11, 13 Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other
LS2A01
500
12371
652
LS2A01 LS2A01 LS2A01
1000 1000 1819
12626 13224 12323
66 107 543
LS2A01
1200
LS2A01
14024
32
10772
445
LS2A01
1000
10329
419
LS2A01
1500
12074
40
LS2A01
1100
13605
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
950
14052
35
LSM12
350
12181
405
LSM12
3
11266
451
LSAII
1000
13280
160
LS2A01
1000
14619
274
LSAII
470
14602
179
14310
544
LS2A01
1000
10667
41
LSAII
500
17793
240
LS2A01
1000
16563
359
LS2A01
1000
11752
32
LS2A01
500
11157
294
LS2A01
1000
LS2A01 LSAII
500
12258 15669
LS2A01
1000
12815
LSM12
LSM12
10475
376
LSM12
6
10369
59
10364 12721 13940 9208
403 338 453 65
LSM12 LSM12
1.5/1.2 5
7991 10593
49 92
LSM12
3
11824
428
1500
10794
323
LS2A01 LS2A01
1000 1000
11330 14591
47 293
LS2A01
1500
16350
338
LS2A01
1500
14537
55
LS2A01 LS2A01 LS2A01
16 1000 500
14665 14800 10557
317 259 257
LS2A01
1000 1000
Cut-off value
IgG
IgG
LSAII
default
20292
273
LMX
Control bead MFI Positive
Control bead MFI Negative
21826
LMX
20211
242
LS2A01
LSM12 LS2A01
Luminex kit (lot)
31
1000 1000 1000 1000 1500
LSAII
Control bead MFI Negative
386 181
LS2A01 LS2A01 LS2A01 LS2A01
12024
Control bead MFI Positive
1.5
LS2A01
1000
Cut-off value IgG
177
LS2A01
LS2A01
Luminex kit (lot) IgG
20138
172
LM2
21844
110
11649 19000
2318 575
LSA I&II
1000
19446
165
LSM12
1000
11154
306
LMX LM2
1000
20487
379/452/900
1000
12086
51
1400
12400
38
LMX
LS2A01 LS2A01 LS2A01
1000
12882
306
LS2A01 LS2A01 LSAII
1000 500
9198 3000 17174
161 500 427
LS2A01
10428
412
LS2PRA LSAII LS2A01 LSAII LSAII LSAII LS2A01
1000 500 1000/500 AD BCR >5 BCM >700 1500 1750
13445 15767 14657 18109 18849 16919 13207
348
LS2A01
500
10450
185
LS2A01
1000
11270
210 256 229 191 377
280
LSM12
3
10923
138
LS2A01
500
14166
98
LSM12
2.5
11660
595
LS2A01 LSAII LS2A01
500
10296 15630 9707
51
LS2PRA
500
10296
51
1500
453
LS2A01
1000
11636
57
LSAII LS2A01
660 1500
16900 14637
216 36
LS2A01 LS2A01
2000 1000
13725 11179
751 315
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-120 Issue 1 P 5 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 03/2016 DESPATCHED ON 26TH JANUARY 2016 HLA specificity for assessment DR17 DR18 Consensus Not Assessed Not Assessed 35.0% 8.8% % reported Lab no. spec tech MFI spec DR17 L < 2000 DR18 9 11 DR17 L < 2000 DR18 12 14 15 19 DR17 L < 2000 20 23 24 DR17 L < 2000 DR18 25 26 DR17 L < 2000 28 34 DR17 L < 2000 35 DR17 L < 2000 38 39 41 DR17 L < 2000 42 45 48 DR17 L < 2000 51 DR17 L < 2000 54 58 62 DR17 L < 2000 100 101 112 DR17 L < 2000 114 116 DR17 L < 2000 117 119 DR17 L < 2000 120 133 136 139 142 143 145 147 149 157 159 160 162 163 DR17 L 2000-5000 DR18 164 DR17 F 165 169 DR17 L < 2000 181 DR17 L < 2000 DR18 185 186 190 193 194 195 DR17 L DR18 197 DR17 L < 2000 204 206 DR17 L < 2000 209 218 227 232 DR17 L > 5000 DR18 235 238 245 DR17 L < 2000 262 267 268 273 DR17 L < 2000 277 284 DR17 L < 2000 292 293 DR17 L < 2000 294 297 DR17 L < 2000 303 DR17 L < 2000 309 311 315 323 Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other No. Reporting Spec Total Participants
28 80
< 2000 24 2000-5000 1 > 5000 1
7 80
L
MFI < 2000
L
tech
< 2000
L
< 2000
L
< 2000
L
< 2000
L
L
< 2000 5 2000-5000 0 > 5000 1
DR12 Present 97.5% spec DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12
tech L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L FL L L L L L L L L L L L L
MFI 2000-5000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000,2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000,2000-5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 > 5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000
DR12 DR12 > 5000 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12 DR12
L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000
DR12
L
2000-5000
78 80
< 2000 23 2000-5000 50 > 5000 1
DR7 Present 100.0% spec DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7 DR7
80 80
tech L L L L L L L L L L L L L L L L L L L L L L L L L L L L L EL L L L L L L L L L L L L L L L L FL L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
< 2000 0 2000-5000 2 > 5000 77
MFI > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
DR9 Present 100.0% spec DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9 DR9
80 80
tech L L L L L L L L L L L L L L L L L L L L L L L L L L L L L EL L L L L L L L L L L L L L L L L FL L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
< 2000 1 2000-5000 27 > 5000 51
MFI > 5000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000,> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 < 2000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 2000-5000
DR52 Present 88.8% spec DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L EL L L L L L L L L L
DR52
L
> 5000
DR52 DR52 DR52 DR52
L L L L
2000-5000 > 5000 2000-5000 > 5000
DR52 DR52 DR52 DR52 DR52 DR52 DR52 DR52
L L L L L L L L
2000-5000 2000-5000 2000-5000 < 2000 > 5000 2000-5000 2000-5000 2000-5000
DR52 DR52 DR52 DR52 DR52 DR52
L L L L L L
2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000
DR52
L
< 2000
DR52 DR52
L L
< 2000 < 2000
DR52 DR52
L L
2000-5000 > 5000
DR52 DR52 DR52 DR52 DR52 DR52 DR52
L L L L L L L
DR52
L
tech
MFI 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000
DR53 Absent 1.3% spec
< 2000 11 2000-5000 47 > 5000 11
MFI
tech
DQ5
L
DQ5
L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000,2000-5000 2000-5000 DR53
71 80
tech
DQ5 Absent 3.8% spec
L
< 2000
DQ2 Present 96.3% MFI spec DQ2 DQ2 < 2000 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2
tech L L L L L L L L L L L L L L L L L L L L L L L L L L L L L EL L L L L L L L L L L L L L L L L FEL L L L L L L L L L L L L
MFI > 5000 2000-5000 > 5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000, > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 > 5000 2000-5000 2000-5000 < 2000,2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000,2000-5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000
L L L L L L
2000-5000 2000-5000 > 5000 < 2000 2000-5000 < 2000
2000-5000 2000-5000 < 2000 2000-5000 > 5000 2000-5000 2000-5000
DQ2 DQ2 < 2000 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2 DQ2
L L L L L L L L L L L
> 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000
2000-5000
DQ2
L
< 2000
1 80
< 2000 1 2000-5000 0 > 5000 0
3 80
L
< 2000 2 2000-5000 0 > 5000 0
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
77 80
< 2000 20 2000-5000 44 > 5000 10
tech
MFI
DQ9 Absent 2.5% spec
tech
DQ9
L
DQ9
L
MFI
2000-5000 < 2000 < 2000
DQ2 DQ2 DQ2 DQ2 DQ2 DQ2
DQ5
DQ7 Absent 1.3% spec
DQ7
1 80
L
< 2000 1 2000-5000 0 > 5000 0
2000-5000
< 2000
2 80
< 2000 0 2000-5000 1 > 5000 0
NEQ-120 Issue 1 P 6 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 03/2016 DESPATCHED ON 26TH JANUARY 2016 Techniques used IgG Lab no. 9 L 11 L 12 L
Sample Treatment IgG
High Background
Dilution EDTA
No No No No No No No No No No
14 15 19 20 23 24 25 26 28
L L L C, L L L L L L
Heat Inactivation, EDTA EDTA EDTA wash buffer EDTA None EDTA EDTA None
No
34 35
L L
EDTA None
No
38 39 41 42 45 48 51
L L L L L L L
EDTA EDTA wash buffer None EDTA EDTA, Adsorption beads Heat Inactivation
No No
54 58 62 100 101 112 114
L L L L L L L
None EDTA None None
No No No No
None EDTA
No No
116 117 119 120 133
C, L EL L L L
None None EDTA EDTA None
No No No No
No No No
136
L
139 142 143 145 147 149 157 159 160 162
L L L L L
None EDTA None None None
No No No No
No
L L L L
EDTA None Adsorption beads EDTA
No No No No
163 164 165 169 181 185 186 190 193 194 195 197 204 206 209 218
L L F, E, L L L L L L L L L L L L C, L L
EDTA None Dilution
No
227 232 235 238 245 262 267 268 273
L L L L L L L C, L L
Dilution, EDTA None DTT None EDTA None None None None
No No No No No No No No
277
L
EDTA
No
284 292
L L
EDTA
No No
None EDTA None EDTA None DTT None None EDTA EDTA EDTA Heat Inactivation
Allele Specific Antibodies
Luminex kit (lot)
Cut-off value IgG
Control bead MFI Negative
Cut-off value
IgG
Control bead MFI Positive
Luminex kit (lot)
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
DP18, 28 DRB3*01:01, 03:01 DQB1*05:01 DPB1*18:01
LS2A01 LS2A01 LS2A01
400 500 500
10110 24 11384
52 5664 41
LSM12 LSM12
2.5 3
275 12279
2828 93
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
1500 1000 1000 500 1000 1000 1000 1000 500
13349 12731 13836 5419 9480 13391 18728 9165 10906
43 56 41 19 17 20 100 36 27
LS2PRA
1000
15995
110
LS2PRA LSAII
1000 1500
14496 19741
45 159
LS2A01 LS2A01
903 1000
12739 12502
84 46
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
1181 1700
10088 13140 9269 10037 12531
37 27 37 52 41
LSAII
476
18621
157
350 1000
10655 11683
17 23
DRB3*01:01, DRB3*01:01, DRB3*01:01, DRB3*01:01, DRB3*01:01,
03:01 03:01 03:01 03:01 03:01
DQA1*05:01 DRB3*01:01, 03:01 DQB1*05:01 DRB3*01:01, 03:01 DRB3*01:01, 03:01 DP18 DRB3*01, 03 DRB3*01:01, 03:01
DRB3*01:01, 03:01 DRB3*01:01, 03:01 DPB1*18:01 DRB3*01, 03 DRB3*01:01, 03:01
800
10929
52
LS2A01 LSM12 LS2A01 LSAII LS2A01 LSAII LS2A01
750 3 1000 393 1000 500 1000
9811 9709 11483 15355 8767 18617 13202
32 15 13.9 194 32 158 13
LSM12 LSAII
LS2A01 LS2A01 LS2A01 LS2A01 LSAII
1000 500 1000 500
9286 11225 7430 8943 13623
22 16 14 23 165
LSM12
03:01 03:01 03:01 09:01, 12:01
03:01
LS2A01
1000
11761
20
DRB3*01:01, 03:01 DRB3*01:01, 03:01
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
1000 1000 1000 1000 1500
9824 9036 11113 12991 10252
21 22 32 66 27
LS2A01 LS2A01 LS2A01 LS2A01
1000 1500 1000 1000
9511 9830 9660 11294
19 42 17 11
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LSAII LSM12 LS2A01 LS2A01 LS2A01 LS2A01
1500 1500 231 1000 500 1000 1000 1000
14393 14210 9933 11400 9756 19661 11476 9900 9421
22 36 43 15 44 163 596 19 13
1400
12700
20
LS2A01 LS2A01 LS2A01 LSAII
1000 1000 500
10751 9593 3000 14903
10 21 500 134
DRB3*01:01, 03:01 DRB1*03:01 DQA1*05:01 DRB3*01:01, DRB3*01:01, DRB3*01:01, DRB1*07:01, DRB3*03:01 DQB1*02:01 DRB3*01:01, DQA1*05:01
DR3*01:01, 03:01 DR3*01:01, 03:01 DR3*01:01, 03:01 MICA = negative DR3*01:01, 03:01 DPB1*18
No
No No No No
DQA1*02
No No No No No
1000 1500
LS2A01
DRB3*01:01, 03:03 DRB3*01:01, DRB1*07:01, DRB3*01:01, DRB3*01:01, DQA1*05:01
03:03 09:01 03:01 03:01
DRB3*01:01, 03:01 DQA1*03:01, 04:01, 05:01 DQA1*01:01, 02:01 DPB1*18:01/DPA1*02:01 DPB1*18:01/DPA1*01:05 DPB1*18:01/DPA1*01:04 DPB11*28:01/DPA1*01:05 DPB1*28:01/DPA1*01:03 DPB1*05:01/DPA1*02:02 DPB1*04:01/DPA1*01:03 DRB3*01:01, 03:01 DRB3*01:01, 03:01 DQA1*05:01
293 L None 294 L None 297 L EDTA No DRB3*01:01, 03:01 303 L EDTA No DP18, 28 309 L None No 311 L EDTA No DRB3*01:01, 03:01 315 L EDTA No 323 L EDTA No Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other
9347
85
LSM12
1.5
11800
61
LSM12
6
10369
29
LSM12 LSM12
1.5/1.2 5
7991 9366
49 29
LSM12
3
8400
29
LM2 LSA I&II
1000
20269 18217
27 132
LSM12
1000
9236
118
LMX LM2
1000
20924
85/110/195
LS2A01 LS2PRA LSAII LS2A01 LSAII LSAII LSAII LS2A01
1000 500 1000/500 AD BCR >5 BCM >700 1500 2037
8139 11123 15578 10634 17759 18464 16628 11373
11 26
LS2A01
500
9036
29
LS2A01 LS2A01
1000 500
8588 12494
14 28
LSM12 LSM12
3 2.5
8295 5407
19 41
LS2A01 LSAII LS2A01 LS2A01 LSAII LS2A01 LS2A01 LS2A01
500
9359 15660 4104 8976 16830 10284 11685 11056
5
LS2PRA
500
9359
5
1500 1000 550 1500 2000 1000
31 177 237 159 40
Luminex kit (lot)
Cut-off value
Control bead MFI Negative
Cut-off value
IgG
Control bead MFI Positive
Luminex kit (lot)
IgG
IgG
IgG
LSAII
default
19414
231
LMX
LMX
Control bead MFI Positive
Control bead MFI Negative
21323
17132
LMX
7 29 223 14 39 14
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-120 Issue 1 P 7 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 04/2016 DESPATCHED ON 26TH JANUARY 2016 HLA specificity for assessment DR16 DR17 Consensus Not Assessed Present 60.0% 80.0% % reported Lab no. spec tech MFI spec tech DR16 L 2000-5000 DR17 L 9 DR16 L < 2000 DR17 L 11 DR16 L 2000-5000 DR17 L 12 DR16 L < 2000 14 15 DR17 L 19 DR16 L < 2000 DR17 L 20 DR16 L < 2000 DR17 L 23 DR16 L < 2000 DR17 L 24 DR17 L 25 26 DR16 L < 2000 DR17 L 28 34 DR17 L 35 DR17 L 38 DR16 L 2000-5000 DR17 L 39 41 DR16 L < 2000 DR17 L 42 DR16 L < 2000 45 DR16 L 2000-5000 DR17 L 48 DR16 L < 2000 DR17 L 51 DR16 L < 2000 DR17 L 54 DR16 L < 2000 DR17 L 58 DR16 L < 2000 DR17 L 62 DR17 L 100 DR16 L < 2000 DR17 L 101 DR17 L 112 DR16 L 2000-5000 DR17 L 114 DR16 L < 2000 DR17 L 116 DR16 L < 2000 DR17 L 117 DR16 L < 2000 DR17 L 119 DR16 L < 2000 DR17 L 120 DR17 L 133 DR16 L < 2000 DR17 L 136 139 DR16 L < 2000 DR17 L 142 DR17 L 143 DR16 L < 2000 DR17 L 145 147 DR17 L 149 DR16 L < 2000 DR17 L 157 DR16 L < 2000 DR17 L 159 DR17 L 160 DR16 L < 2000 DR17 L 162 163 DR16 L 2000-5000 DR17 L 164 DR17 FEL 165 DR17 L 169 DR16 L < 2000 DR17 L 181 DR17 L 185 DR17 L 186 DR16 L 2000-5000 DR17 L 190 DR16 L < 2000 DR17 L 193 DR16 L < 2000 DR17 L 194 DR16 L < 2000 DR17 L 195 DR17 L 197 DR16 L < 2000 DR17 L 204 DR16 L < 2000 DR17 L 206 DR16 L < 2000 DR17 L 209 DR17 L 218 DR17 L 227 DR16 L < 2000 232 235 DR17 L 238 DR16 L < 2000 DR17 L 245 DR17 L 262 267 DR17 L 268 DR16 L < 2000 DR17 L 273 DR16 L < 2000 DR17 L 277 DR16 L < 2000 284 DR16 L < 2000 DR17 L 292 DR16 L < 2000 DR17 L 293 DR17 L 294 DR16 L < 2000 297 DR16 L < 2000 DR17 L 303 DR17 L 309 DR16 L 2000-5000 DR17 L 311 315 DR16 L < 2000 323 Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other No. Reporting Spec Total Participants
48 80
< 2000 40 2000-5000 8 > 5000 0
64 80
< 2000 59 2000-5000 4 > 5000 0
MFI 2000-5000 < 2000 < 2000
DR18 Not Assessed 68.8% spec DR18 L DR18 L DR18 L
< 2000 < 2000 < 2000 < 2000 < 2000
DR18 DR18 DR18 DR18 DR18
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
< 2000
DR18
L
< 2000
DR4 DR4 DR4 DR4 DR4 DR4
< 2000 < 2000 < 2000
DR18 DR18 DR18
L L L
< 2000 < 2000 < 2000
DR4 DR4 DR4
L L L
< 2000 < 2000 < 2000
DR11 DR11 DR11
L L L
2000-5000 < 2000 2000-5000
< 2000
DR18
L
< 2000
DR4
L
< 2000
DR18 DR18 DR18
L L L
< 2000 < 2000 < 2000
DR4 DR4 DR4 DR4
L L L L
< 2000 < 2000 < 2000 < 2000
DR18 DR18 DR18 DR18 DR18 DR18 DR18 DR18 DR18 DR18
L L L L L L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000
DR4 DR4 DR4 DR4 DR4
L L L L L
2000-5000 < 2000 < 2000 < 2000 < 2000
DR4
L
< 2000
DR18 DR18
L L
< 2000 < 2000
DR4 DR4 DR4
L L L
< 2000 < 2000 < 2000,2000-5000
DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11
L L L L L L L L L L L L L L L L L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
DR18 DR18
L L
< 2000 < 2000
DR4
L
< 2000
DR18 DR18
L L
< 2000 < 2000
DR4 DR4
L L
< 2000 < 2000< 2000
2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000
DR18
L
< 2000
DR4 DR4
L FL
2000-5000 < 2000
DR11 DR11 DR11 DR11 DR11 DR11 DR11
2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000
tech
MFI 2000-5000 < 2000 < 2000
DR18 DR18 DR18 DR18
L L L L
< 2000 < 2000 < 2000 < 2000
DR18 DR18
L L
< 2000
DR4 Not Assessed 56.3% spec DR4 DR4 DR4 DR4
DR11 Present 92.5% spec DR11 DR11 DR11 DR11
L L L L
< 2000 < 2000 < 2000 < 2000
L L L L
MFI 2000-5000 < 2000 2000-5000 < 2000
L L L L L L
< 2000 < 2000 2000-5000 < 2000 < 2000
DR11 DR11 DR11 DR11 DR11 DR11 DR11
L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000
tech
MFI
DR4
L
< 2000
DR4
L
< 2000
DR4 DR4
L L
< 2000 < 2000
DR4
L
< 2000
DR4
L
< 2000
DR4
L
< 2000
DR4 DR4
L L
< 2000 < 2000
< 2000 < 2000 < 2000 < 2000 < 2000
DR18 DR18 DR18 DR18
L L L L
< 2000 < 2000 < 2000 < 2000
< 2000 < 2000 < 2000
DR18 DR18 DR18
L L L
< 2000 < 2000 < 2000
< 2000 < 2000 < 2000
DR18 DR18 DR18
L L L
< 2000 < 2000 < 2000
< 2000 < 2000 < 2000
DR18 DR18 DR18
L L L
< 2000 < 2000 < 2000
DR4 DR4
L L
< 2000 < 2000
< 2000 < 2000 2000-5000
DR18 DR18 DR18
L L L
< 2000 < 2000 < 2000
DR4
L
< 2000
DR4
L
2000-5000
55 80
< 2000 53 2000-5000 1 > 5000 0
45 80
< 2000 39 2000-5000 4 > 5000 0
tech
DR12 Not Assessed 60.0% spec DR12 L DR12 L DR12 L
tech
MFI 2000-5000 < 2000 < 2000
DR12 DR12 DR12 DR12
L L L L
< 2000 < 2000 < 2000 < 2000
DR12
L
< 2000
DR12 DR12
L L
< 2000 < 2000
< 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000,2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000
DR12
L
< 2000
DR12 DR12 DR12 DR12 DR12 DR12
L L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000 < 2000
DR12
L
< 2000
DR12
L
< 2000
DR12
L
< 2000
DR12
L
< 2000
DR12
L
< 2000
L L L L L L L
< 2000 2000-5000 < 2000 < 2000 2000-5000 < 2000 2000-5000
DR12 DR12
L L
< 2000 < 2000
DR12
L
< 2000
DR12 DR12
L FL
< 2000 < 2000
DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11 DR11
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 < 2000 < 2000 < 2000 2000-5000 < 2000 < 2000 2000-5000
DR12 DR12 DR12 DR12
L L L L
< 2000 < 2000 < 2000 < 2000
DR12
L
< 2000
DR12 DR12 DR12 DR12 DR12
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
DR12 DR12
L L
< 2000 < 2000
DR12 DR12 DR12
L L L
< 2000 < 2000 2000-5000
DR12 DR12 DR12
L L L
< 2000 < 2000 < 2000
DR12 DR12 DR12
L L L
< 2000 < 2000 2000-5000
DR11
L
< 2000
74 80
< 2000 44 2000-5000 28 > 5000 0
2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000
48 80
< 2000 45 2000-5000 3 > 5000 0
DR13 Present 95.0% spec DR13 DR13 DR13 DR13
L L L L
MFI 2000-5000 < 2000 2000-5000 < 2000
DR13 DR13 DR13 DR13 DR13 DR13 DR13
L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000
DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13 DR13
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L FL L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000,2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 2000-5000 < 2000,2000-5000 < 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000
76 80
tech
< 2000 < 2000 < 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000
< 2000 42 2000-5000 31 > 5000 0
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-120 Issue 1 P 8 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 04/2016 DESPATCHED ON 26TH JANUARY 2016 HLA specificity for assessment DR14 DR1403 Consensus Present Absent 96.3% 2.5% % reported Lab no. spec tech MFI spec tech L 2000-5000 9 DR14 L < 2000 11 DR14 L 2000-5000 12 DR14 L < 2000 14 DR14 15 L 2000-5000 19 DR14 L 2000-5000 20 DR14 L 2000-5000 23 DR14 L 2000-5000 24 DR14 L 2000-5000 25 DR14 L < 2000 26 DR14 L < 2000 28 DR14 34 L 2000-5000 35 DR14 L 2000-5000 38 DR14 L 2000-5000 39 DR14 L 2000-5000 41 DR14 L < 2000 42 DR14 L 2000-5000 45 DR14 L 2000-5000 48 DR14 L 2000-5000 51 DR14 L 2000-5000 54 DR14 L < 2000 58 DR14 L 2000-5000 62 DR14 L < 2000 100 DR14 L < 2000 101 DR14 L < 2000 112 DR14 L 2000-5000 114 DR14 L < 2000 116 DR14 L < 2000 117 DR14 L < 2000,2000-5000 119 DR14 L 2000-5000 120 DR14 L < 2000 133 DR14 L 2000-5000 136 DR14 L < 2000 139 DR14 L 2000-5000 142 DR14 L 2000-5000 143 DR14 L < 2000,2000-5000 145 DR14 L < 2000 147 DR14 L < 2000 149 DR14 L 2000-5000 157 DR14 L < 2000 159 DR14 L < 2000 160 DR14 L 2000-5000 162 DR14 L 2000-5000 163 DR14 L 2000-5000 164 DR14 FL 2000-5000 165 DR14 L 2000-5000 169 DR14 L < 2000 181 DR14 L < 2000 185 DR14 L < 2000 186 DR14 L 2000-5000 190 DR14 L 2000-5000 193 DR14 L < 2000 194 DR14 L 2000-5000 195 DR14 L 197 DR14 L 2000-5000 204 DR14 L < 2000 206 DR14 L < 2000 209 DR14 L < 2000 218 DR14 L 2000-5000 227 DR14 L < 2000 232 DR14 L < 2000 235 DR14 L < 2000 238 DR14 L 2000-5000 DR1403 L 245 DR14 L < 2000 262 DR14 L < 2000 267 DR14 L < 2000 268 DR14 L 2000-5000 273 DR14 L 2000-5000 277 DR14 L < 2000 284 DR14 L 2000-5000 292 DR14 L < 2000 293 DR14 L < 2000 294 DR14 L 2000-5000 297 DR14 L 2000-5000 303 DR14 L < 2000 DR1403 L 309 DR14 L 2000-5000 311 DR14 315 L < 2000 323 DR14 Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 77 80
< 2000 35 2000-5000 39 > 5000 0
2 80
< 2000 0 2000-5000 0 > 5000 0
MFI
DR1404 Not Assessed 11.3% spec
tech
DR1404
L
DR1404
L
DR1404
L
DR8 Present 98.8% MFI spec DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 < 2000 DR8 DR8 < 2000 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 < 2000 DR8 DR8 DR8 DR8 DR8 DR8
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L FL L L L L L L L L
tech
MFI 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 < 2000 < 2000 2000-5000
L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 < 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000
DR51 Absent 1.3% spec
DR1404
L
< 2000
DR1404 DR1404
L L
< 2000
DR1404
L
< 2000
DR1404
DR1404
9 80
L
L
< 2000 8 2000-5000 0 > 5000 0
< 2000
< 2000
79 80
< 2000 37 2000-5000 42 > 5000 0
tech
MFI < 2000
DR52
L
< 2000
DR52
L
< 2000
DR52
L
< 2000
DR52
L
DR52
L
< 2000
DR52 DR52 DR52
L L L
2000-5000 < 2000 < 2000
DR52
L
< 2000
DR52
L
< 2000
DR52
L
< 2000
DR52 DR52 DR52
L L L
< 2000 < 2000 < 2000
DR53 Absent 1.3% spec
DR53
DR51 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8 DR8
tech
DR52 Not Assessed 41.3% MFI spec DR52 L
1 80
L
< 2000 0 2000-5000 0 > 5000 0
DR52
L
< 2000
DR52 DR52 DR52 DR52 DR52
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
DR52 DR52
L L
< 2000
DR52 DR52 DR52 DR52
L L L L
< 2000 < 2000 < 2000 < 2000
L L
< 2000 < 2000
DR52
L
< 2000
DR52 DR52 DR52
L L L
< 2000 < 2000 2000-5000
< 2000 29 2000-5000 2 > 5000 0
L
MFI
1 80
< 2000 1 2000-5000 0 > 5000 0
tech
DQ4 Absent 2.5% MFI spec
tech
MFI
< 2000
DQ8
DR52 DR52
33 80
tech
DQ8 Absent 1.3% spec
1 80
L
< 2000 0 2000-5000 0 > 5000 0
DQ4
L
DQ4
L
2 80
< 2000
< 2000 1 2000-5000 0 > 5000 0
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-120 Issue 1 P 9 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 04/2016 DESPATCHED ON 26TH JANUARY 2016 Techniques used IgG
Sample Treatment IgG
High Allele Specific Antibodies Background IgG
Luminex kit (lot)
Cut-off value
Control bead MFI Negative
Cut-off value
IgG
Control bead MFI Positive
Luminex kit (lot)
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
None
LS2A01 LS2A01 LS2A01
400 500 500
8050 27 9450
59 4075 36
LSM12 LSM12
2.5 3
73 9120
2953 61
LS2A01 LS2A01 LS2A01 LS2A01
1500 1000 1000 500
10668 10332 11894 9275
36 18 20 39
LS2A01 LS2A01
1000 1000
8728 11382
24 31
LS2PRA
1000
14558
51
LS2A01 LS2A01 LS2A01
1000
16509 7173 8783
710 69 39
LSAII
1500
20172
166
35 62 42 13 49 33
LSAII
18797
142
Lab no. 9 L 11 L 12 L
EDTA
No No No
14 15 19 20
L L L C, L
Heat Inactivation, EDTA EDTA EDTA wash buffer EDTA
No No No No
23 24
L L
None EDTA
No No
25 26 28
L L L
EDTA EDTA None
Yes
34 35 38 39 41 42
L L L L L L
EDTA None EDTA EDTA wash buffer None EDTA
No No No No
45 48 51
L L L
EDTA, Adsorption beads Heat Inactivation
No No
No
DRB1*04:04 DRB1*04:01, 04:03, 04:04 DPB1*01:01, 19:01 DRB1*04:04
DRB1*04:01, 04:03, 04:04 DRB3*02:02, 03:01 DPB1*01:01, 19:01 DPA1*01:03, 02:01 DRB1*04:04, 12:01 DRB1*04:04, 12:01, 14:01, 14:54 DRB3*03:01 DRB1*04:01, 04:04 DRB1*04:04, 14:01, 14:54 DRB1*04:01, 04:03, 04:04 DRB3*02:02, 03:01
No
54
L
None
No
58 62 100 101 112 114 116 117
L L L L L
EDTA None
No No
None None
No No
C, L EL
None None
No No
119 120
L L
EDTA EDTA
No No
None
133
L
136 139 142 143 145 147 149 157 159 160 162
L L L L L L
None EDTA None None
No No No No No
L L L L
EDTA None Adsorption beads EDTA
No No No No
163 164 165 169 181 185 186 190 193 194 195 197 204 206 209
L L F, E, L L L L L L L L L L L L C, L
EDTA None Dilution
No
None EDTA None EDTA None DTT None None EDTA EDTA EDTA
No No
No No No
DRB1*04:01, 04:04 DRB1*04:04 DRB1*04:01, 04:04 DRB1*13:03, 14:01 DRB1*04:04, 14:54 DRB3*03:01 DRB3*03:01 DRB1*04:01, 04:03, 04:04 DRB3*02:02, 03:01 DRB1*04:04 DRB3*03 DRB1*04:04
DP1, 19 DRB1*04:04 DRB1*04:01, 04:04 DRB3*03:01 DRB1*04:04 DRB1*04:01, 04:03, 04:04 DRB3*03:01 DP19 DRB1*03:01, 03:02, 03:03, 08:01, 11:01, 11:04, 13:01, 13:03, 14:01, 14:04 DRB3*03:01 DRB1*04:04, 14:01, 14:54 DRB1*13:03
DRB1*04:04 DRB1*13:03, 14:01 DRB1*04:04, 12:01 DRB1*04:04 DRB1*04:04, 14:01, 14:54 MICA = negative DRB1*04:01, 04:04
No DP19 DRB3*03:01 No No No
218
L
Heat Inactivation
No
227 232 235 238 245 262 267 268 273
L L L L L L L C, L L
Dilution, EDTA None DTT None EDTA None None None None
No No No No No No No No
277
L
EDTA
No
284 292
L L
EDTA EDTA
No No
293 294 297 303
L L L L
None None EDTA EDTA
No No
309 311
L L
None EDTA
No
DRB1*04:01, 12:01, 14:01, 14:54
1000
17285 11562 9692 12063 7357 8062
LS2A01
DRB1*04:04 DRB3*03:01 DRB3*03:01 DRB1*04:04 DRB3*03:01
315 L EDTA No 323 L EDTA No Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other
1000 1000 918 1200
1500
8999
18
LS2A01
800
6766
505
LSM12
350
9448
101
LSM12 LS2A01 LSAII LS2A01 LSAII LS2A01 LS2A01 LS2A01
3 1000 390 1000 500 1000 1000 500
9595 9618 13463 7878 17937 11283 7427 8757
22 65 170 30 167 50 22 49
LSAII
1000
9753
23
7459
44
LS2A01 LS2A01
1000 500
6596 7413
16 29
LSM12
1.5
7662
23
LSM12
6
8621
26
LSM12 LSM12
1.5/1.2 5
7991 8047
49 26
LSM12
3
8100
59
LM2 LSA I&II
1000
20478 19425
63 161
LSM12
1000
8863
72
LMX LM2
1000
20759
65/76/130
Cut-off value
Control bead MFI Positive
Control bead MFI Negative
Luminex kit (lot)
Cut-off value
IgG
IgG
IgG
LSAII
default
19833
141
LMX
Control bead MFI Positive
Control bead MFI Negative
19264
LS2A01
LSAII
14702
108
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
1000 1000 1000 1000 1000 1500
9368 8029 6739 11426 6203 10252
25 20 222 33 31 28
LS2A01 LS2A01 LS2A01 LS2A01
1000 1500 1000 1000
8835 8167 9500 10700
41 29 16 20
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LSAII LSM12 LS2A01 LS2A01 LS2A01 LS2A01
1500 1500 210 1000 500 1000 1000 1000
13767 10437 9054 8400 7087 18831 7795 8600 8186
35 38 43 23 35 116 58 26 15
1400
10400
34
LS2A01 LS2A01 LS2A01
1000 1000 500
9235 7214 3000
14 30 500
14700
158
13 27
DRB1*04:01, 04:04 DRB3*03:01 DRB1*03:01, 03:02, 03:03, 08:01, 11:01, 11:04, LSAII 12:01, 13:01, 13:03, 14:01, 14:04 DRB3*01:01, 03:01
DRB1*04:04 DRB3*03:01 DRB1*04:01, 04:03, 04:04 DRB3*03:01 DPB1*19:01/DPA1*01:03 DRB1*04:04 DRB1*04:01, 04:03, 04:04, 16:02 DPB1*19:01
500
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
Luminex kit (lot) IgG
LSM12
LS2A01 LS2PRA LSAII LS2A01 LSAII LSAII LSAII LS2A01
1000 500 1000/500 AD BCR >5 BCM >700 1500 857
6646 10026 16934 9049 16248 19066 15700 8916
25 240 173 134 33
LS2A01
500
7317
30
LS2A01 LS2A01
1000 500
8020 12143
18 48
LSM12 LSM12
3 2.5
8096 3089
21 38
LS2A01 LSAII LS2A01 LS2A01
500
7457 15158 4778 7171
6
LS2PRA
500
7457
6
1500 1000
17 26
LSAII LS2A01
1500
20100 9594
450 28
LS2A01 LS2A01
2000 1000
11257 9662
33 11
LMX
19484
LMX
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-120 Issue 1 P 10 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 05/2016 DESPATCHED ON 26TH JANUARY 2016 HLA specificity for assessment DR1 DR103 DR15 Consensus Absent Absent Absent 1.3% 2.5% 1.3% % reported Lab no. spec tech MFI spec tech MFI spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 101 112 114 116 117 119 120 133 136 139 142 DR103 L < 2000 143 145 147 149 157 159 160 162 163 164 165 169 181 NT NT NT NT NT NT NT NT 185 186 190 193 194 195 DR1 L DR103 L DR15 L 197 204 206 209 218 227 232 235 238 245 262 267 268 273 277 284 292 293 294 297 303 309 311 315 323 Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other No. Reporting Spec Total Participants
1 79
< 2000 0 2000-5000 0 > 5000 0
2 79
< 2000 1 2000-5000 0 > 5000 0
1 79
< 2000 0 2000-5000 0 > 5000 0
DR16 Absent 1.3% MFI spec
NT
tech
NT
NT
DR16
L
1 79
< 2000 0 2000-5000 0 > 5000 0
DR4 Absent 2.5% MFI spec
NT
tech
MFI
DR4
L
< 2000
NT
NT
NT
DR4
L
2 79
< 2000 1 2000-5000 0 > 5000 0
DR11 Absent 2.5% spec
tech
MFI
DR13 Absent 2.5% spec
tech
MFI
DR14 Absent 1.3% spec
tech
MFI
DR8 Absent 1.3% spec
tech
MFI
DR11
L
< 2000 DR13
L
< 2000 DR14
L
< 2000 DR8
L
< 2000
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
DR11
L
DR13
L
2 79
< 2000 1 2000-5000 0 > 5000 0
2 79
< 2000 1 2000-5000 0 > 5000 0
NT
1 79
< 2000 1 2000-5000 0 > 5000 0
NT
1 79
< 2000 1 2000-5000 0 > 5000 0
DR10 Absent 1.3% spec
tech
NT
NT
DR10
L
1 79
DR51 Absent 1.3% MFI spec
NT
< 2000 0 2000-5000 0 > 5000 0
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
tech
NT
NT
DR51
L
1 79
< 2000 0 2000-5000 0 > 5000 0
DR53 Absent 1.3% MFI spec
NT
tech
NT
NT
DR53
L
1 79
MFI
NT
< 2000 0 2000-5000 0 > 5000 0
NEQ-120 Issue 1 P 11 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 05/2016 DESPATCHED ON 26TH JANUARY 2016 HLA specificity for assessment DQ5 DQ6 DQ7 Consensus Absent Absent Not Assessed 1.3% 1.3% 15.2% % reported Lab no. spec tech MFI spec tech MFI spec 9 11 DQ7 12 14 15 19 20 23 24 25 26 DQ7 28 34 35 38 39 41 DQ7 42 45 48 DQ7 51 54 58 62 100 101 112 114 116 117 119 120 133 136 139 142 DQ7 143 145 147 149 157 159 160 162 163 164 165 169 181 NT NT NT NT NT NT 185 NT 186 DQ7 190 193 DQ7 194 195 L DQ6 L DQ7 197 DQ5 204 206 209 218 DQ7 227 232 235 238 DQ7 245 262 267 268 273 DQ7 277 284 292 293 294 297 DQ7 303 309 311 315 323 Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 79
< 2000 0 2000-5000 0 > 5000 0
1 79
< 2000 0 2000-5000 0 > 5000 0
12 79
tech
L
MFI
< 2000
L
DQ8 Not Assessed 15.2% spec
DQ8
tech
L
DQ8
L
MFI
< 2000
DQ9 Not Assessed 17.7% spec
tech
MFI
DQ9
L
< 2000
DQ9
L
< 2000
DQ9
L
L
< 2000
DQ8
L
< 2000
DQ9
L
< 2000
L
2000-5000
DQ8
L
2000-5000
DQ9
L
2000-5000
DQ9
L
< 2000
L
< 2000
DQ8
L
< 2000
DQ9
L
< 2000
NT
NT
NT
NT
NT
NT
NT
NT
L
< 2000
DQ8
L
< 2000
DQ9
L
< 2000
L
< 2000
DQ8
L
< 2000
DQ9
L
< 2000
L
DQ8
L
< 2000
DQ9
L
< 2000
L
< 2000
DQ8
L
< 2000
DQ9
L
2000-5000
L
< 2000
DQ8
L
< 2000
DQ9
L
< 2000
L
< 2000
DQ8
L
< 2000
DQ9
L
< 2000
L
< 2000
DQ8
L
< 2000
DQ9
L
< 2000
< 2000 9 2000-5000 1 > 5000 0
12 79
< 2000 10 2000-5000 1 > 5000 0
14 79
< 2000 11 2000-5000 2 > 5000 0
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-120 Issue 1 P 12 of 13 Effective Date 16/03/16
UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 3 05/2016 DESPATCHED ON 26TH JANUARY 2016 Techniques used IgG Lab no. 9 L 11 L 12 L
Sample Treatment IgG
High Allele Specific Antibodies Background IgG
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
None EDTA
No No No
LS2A01 LSM12 LS2A01
800 2.5 500
7775 73 10314
82 2953 121
LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LM2 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
1500 1000 1000 500 1000 1000 6 1000 500 1000 1000
11422 11493 13397 7904 8679 11773 9284 12772 10248 11174 11465 10007 10948 7467 7530 12478
29 27 36 36 24 63 126.79 126 39.8 17 72 38 18 38 41 24
LS2A01 LS2A01 LSM12 LS2A01 LSAII LS2A01 LSAII LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LSAII LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LSM12
500 1000 3 1000 506 1000 500 1000 1000 500 1000 500 1000 1000 1000 1000 1000 8773
12240 11013 8530 10722 15547 7750 17657 9905 7502 9653 6770 7907 14054 9368 7886 7680 13651 11806 5
94 36 16 62 135 77 143 17 27 49 17 53 211 24 41 33 60 50 46
14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 101 112 114 116 117 119 120 133 136 139 142 143 145 147 149 157 159 160 162 163 164 165 169 181 185
L L L C, L L L L L L L L L L L L L L L L L L L L L C, L C, L EL L L L L L L L L L
Heat Inactivation, EDTA EDTA EDTA wash buffer EDTA None EDTA EDTA
No No No No No No No
None EDTA None EDTA EDTA wash buffer None EDTA EDTA, Adsorption beads Heat Inactivation
No No No No No No No No No
None EDTA None
No No No
None None EDTA None None EDTA EDTA None
No No No No No No No
L L L L L L F, E, L L L L
EDTA None Adsorption beads EDTA EDTA None Dilution Dilution None EDTA
No Yes
186 190 193 194 195 197 204 206 209 218 227 232 235 238 245
L L L L L L L L C, L L L L L L L
None EDTA None
No No No
None None EDTA EDTA EDTA Heat Inactivation Dilution, EDTA None DTT, Adsorption beads None EDTA
No
DQA1*03:02 has been interpreted as causing positivity seen against DQB1*03:02, 03:03 DQA1*05:03, 05:05, 06:01 has been interpreted as causing positivity seen against DQB1*03:01
DQA1*03:02
DQA1*03:02, 05:03, 05:05, 06:01
DQA1*03:02, 05:05, 06:01
DP13
None EDTA None None None
DRB1*11:01, 13:03, 14:01, 14:54 DQA1*03:02, 05:05
No No No No No
No No No No No
DQA1*03:02, 05:05
LS2A01 LS2A01
1500
9344 17145
18 86
MICA = negative
LSM12 LS2A01 LS2A01 LS2A01 LS2A01 LS2A01
3 1500 1500 45 1000 500
7400 11900 10437 10076 9800 7707
19 25 38 223 30 187
LSM12 LS2A01 LS2A01 LS2A01 LS2A01
1000 1000 1000
9459 8580 7318
223 38 14
1400
12700
30
LS2A01 LS2A01 LS2A01 LSAII
1000 1000 500
9130 7733 3000 15143
12 25 500 193
8261 10743 15833 12322
28 374
182 168 151 71 109 25 38 21
28 46 18
No DQA1*03:02, 05:03, 05:05, 06:01 Aspecific reactions epitopes 46VY3? All DQ except DQ2 are reactive. High background also for DR & DP.
DQA1*03:02, 05:05
No No No No No No Yes No No
1000 1500
DQA1*03:02
DQA1*03:02, 05:03, 05:05, 06:01 (in our protocol HLA-DQ7, DQ8 and DQ9 wouldn't be assigned as present)
262 L None No 267 L Sera Clean No 268 C, L None No 273 L None No 277 L EDTA No DQA1*03:02, 05:03, 05:05, 06:01 284 L EDTA No 292 L EDTA No 293 L None 294 L None 297 L EDTA 303 L EDTA No 309 L None No 311 L EDTA No 315 L EDTA No DQA*03 323 L EDTA No Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other
LS2A01 LS2PRA LSAII LS2A01
1000 500 1000/500
LSAII LSAII LSAII LS2A01 LS2A01 LS2A01 LS2A01 LS2A01 LSAII LS2A01 LS2A01
AD BCR >5 BCM >700 1500 1311 500 1000 500 500 1500 1000
17863 19208 15686 11111 9881 8250 10975 7288 15167 4765 8760
LS2A01 LS2A01 LS2A01
1500 2000 1000
9336 10224 9724
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LSM12
3
10721
202
LS2PRA
1000
12136
33
18385
171
8609 10566
13 45
LSAII
LSM12 LSAII
350 1000
LSM12
7824
59
LSM12
1.5
10381
35
LSM12
6
8396
33
LSM12
1.5/1.2
7991
49
LSA I&II
1000
19502
151
LSM12
1000
11251
293
LMX LM2
1000
20296
31/102/135
LSM12 LSM12 LS2PRA
3 2.5 500
7553 6589 7288
20 50 21
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
IgG
LSAII
default
17527
160
LMX
LMX
Luminex kit (lot) Cut-off value Control bead MFI IgG Positive
Control bead MFI Negative
18076
17379
36
25 183
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-120 Issue 1 P 13 of 13 Effective Date 16/03/16
